Frontage Laboratories, a global contract research, development, and manufacturing organization (CRO/CDMO), announced that it has completed the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd., a clinical research laboratory service provider based in China. The deal is intended to expand Frontage’s global laboratory service capabilities while strengthening its presence in China and the broader Asia-Pacific region.
Teddy Lab has supported more than 1,500 clinical trials across a wide range of therapeutic areas. The laboratory is known for operating under Good Clinical Practice (GCP)-compliant systems and maintains internationally recognized accreditations. Its operations include CAP-accredited and NGSP Level 1 certified quality systems, as well as qualification as a Class II Unsealed Radioactive Material Workplace. The company has also contributed to the successful regulatory approval of more than 50 new drugs.
With the addition of Teddy Lab, Frontage has expanded its central laboratory footprint in China. The company expects the enhanced capabilities to help meet increasing demand for both domestic Chinese clinical trials and multi-regional clinical trials. By combining Teddy Lab’s central laboratory expertise with Frontage’s broader service platform, the company aims to provide more integrated support for pharmaceutical and biotechnology companies conducting global drug development programs.
Frontage’s service platform includes capabilities in bioanalytical services, drug metabolism and pharmacokinetics (DMPK), safety and toxicology studies, chemistry, manufacturing, and controls (CMC), and clinical trial support. The integration of Teddy Lab is expected to strengthen the company’s position as a comprehensive service provider across multiple stages of drug development.
Frontage Laboratories, a wholly owned subsidiary of Frontage Holdings Corporation, provides end-to-end integrated product development services spanning drug discovery through late-phase clinical trials and manufacturing.
The company has more than 25 years of experience supporting pharmaceutical and biotechnology companies with services including API synthesis, formulation development, GMP manufacturing, analytical services, clinical trials, and central laboratory operations. Frontage operates 26 sites worldwide and has supported regulatory approvals for clients across the United States, Canada, Europe, and Asia.
